Literature DB >> 19396561

Expression of full-length human pro-urokinase in mammary glands of transgenic mice.

Yaroslav Gursky1, Robert Bibilashvili, Mikchail Minashkin, Alex Krasnov, Alex Deikin, Tatyana Ermolkevich, Andrey Popov, Lilia Verbovaya, Nicolai Rutkevich, Alexsander Shevelev, Sofia Georgieva, Sergey V Razin, Igor Goldman, Elena Sadchikova.   

Abstract

Human pro-urokinase expressed in the mammary glands of transgenic animals is quickly activated and converted to urokinase by proteases that are present in the milk. Thus, it is nearly impossible to isolate full-sized pro-urokinase from the milk of transgenic animals. To solve this problem, we constructed transgenic mice that express human pro-urokinase and modified ecotin, which is a potent serine protease inhibitor from E. coli, in their mammary glands. The gene encoding ecotin was modified so as to enhance its specificity for the human urokinase-type plasminogen activator. Co-expression of modified ecotin and human pro-urokinase in the mammary glands allows for purification of full-length human pro-urokinase from these transgenic mice. The results described here suggest a general way of preventing the activation of zymogens that are expressed in the mammary glands of transgenic animals by co-expression of a zymogen along with a protease inhibitor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396561     DOI: 10.1007/s11248-009-9269-9

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  26 in total

1.  In vitro renaturation of recombinant human pro-urokinase expressed in Escherichia coli.

Authors:  H Zhu; W Liu; W Shi; Y Xue; L Kuai; Z Ma
Journal:  Chin Med J (Engl)       Date:  2001-02       Impact factor: 2.628

Review 2.  Treatment of acute ischemic stroke: recent progress.

Authors:  Norio Tanahashi; Yasuo Fukuuchi
Journal:  Intern Med       Date:  2002-05       Impact factor: 1.271

3.  The fibrin plate method for estimating fibrinolytic activity.

Authors:  T ASTRUP; S MULLERTZ
Journal:  Arch Biochem Biophys       Date:  1952-10       Impact factor: 4.013

Review 4.  Transgenic animal bioreactors in biotechnology and production of blood proteins.

Authors:  H Lubon
Journal:  Biotechnol Annu Rev       Date:  1998

5.  Expression in Escherichia coli of biologically active enzyme by a DNA sequence coding for the human plasminogen activator urokinase.

Authors:  B Ratzkin; S G Lee; W J Schrenk; R Roychoudhury; M Chen; T A Hamilton; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

6.  Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.

Authors:  K Ouriel; K Kandarpa; D M Schuerr; M Hultquist; G Hodkinson; B Wallin
Journal:  J Vasc Interv Radiol       Date:  1999-09       Impact factor: 3.464

Review 7.  Transgenic animals in medicine: integration and expression of foreign genes, theoretical and applied aspects.

Authors:  Igor L Goldman; Sergei G Kadulin; Sergei V Razin
Journal:  Med Sci Monit       Date:  2004-10-26

8.  Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.

Authors:  S Q Yang; C S Craik
Journal:  J Mol Biol       Date:  1998-06-19       Impact factor: 5.469

9.  Use of the urokinase-type plasminogen activator gene as a general tool to monitor expression in transgenic animals: study of the tissue-specificity of the murine whey acidic protein (WAP) expression signals.

Authors:  A Brandazza; E Lee; M Ferrera; U Tillman; P Sarmientos; H Westphal
Journal:  J Biotechnol       Date:  1991-09       Impact factor: 3.307

10.  Bovine alpha S1-casein gene sequences direct high level expression of active human urokinase in mouse milk.

Authors:  H Meade; L Gates; E Lacy; N Lonberg
Journal:  Biotechnology (N Y)       Date:  1990-05
View more
  1 in total

1.  Use of transgenic animals in biotechnology: prospects and problems.

Authors:  O G Maksimenko; A V Deykin; Yu M Khodarovich; P G Georgiev
Journal:  Acta Naturae       Date:  2013-01       Impact factor: 1.845

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.